Advancing Drug Safety in Drug Development: Bridging Computational Predictions for Enhanced Toxicity Prediction
Open accessThe DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Abstract
The attrition rate of drugs in clinical trials is generally quite high, with estimates suggesting that approximately 90% of drugs fail to make it through the process. The identification of unexpected toxicity issues during preclinical stages is a significant factor contributing to this high rate of failure. These issues can have a major impact on the success of a drug and must be carefully considered throughout the development process. These late-stage rejections or withdrawals of drug candidates significantly increase the costs associated with drug development, particularly when toxicity is detected during clinical trials or after market release. Understanding drug-biological target interactions is essential for evaluating compound toxicity and safety, as well as predicting therapeutic effects and potential off-target effects that could lead to toxicity. This will enable scientists to predict and assess the safety profiles of drug candidates more accurately. Evaluation of toxicity and safety is a critical aspect of drug development, and biomolecules, particularly proteins, play vital roles in complex biological networks and often serve as targets for various chemicals. Therefore, a better understanding of these interactions is crucial for the advancement of drug development. The development of computational methods for evaluating protein-ligand interactions and predicting toxicity is emerging as a promising approach that adheres to the 3Rs principles (replace, reduce, and refine) and has garnered significant attention in recent years. In this review, we present a thorough examination of the latest breakthroughs in drug toxicity prediction, highlighting the significance of drug-target binding affinity in anticipating and mitigating possible adverse effects. In doing so, we aim to contribute to the development of more effective and secure drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Advancing drug safety assessment relies on bridging the translation gap between animal toxicology findings and clinical outcomes, a challenge with far-reaching consequences for R&D efficiency, regulatory success and patient safety (Waring et al., 2015; Amorim et al., 2024).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Amorim et al., 2024
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
XGBoost: A Scalable Tree Boosting System
Chen, T., & Guestrin, C. (2016) · Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining · doi:10.1145/2939672.2939785 · Cited by 54,569 · cited 1×
“Using an ensemble approach that leverages DNN, RF, and extreme Gradient Boosting (XGBoost), 62 they also examined the contribution of each input fingerprint to the prediction output, thus gaining insight into warning substructures that might be indicative of the cardiotoxicity of the input compound.”
MethodDrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
PubChem in 2021: new data content and improved web interfaces
Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa971 · Cited by 3,953
Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac956 · Cited by 3,443
Xiong, G., Wu, Z., Yi, J., Fu, L., Yang, Z., Hsieh, C., Yin, M., Zeng, X., Wu, C., Lu, A., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab255 · Cited by 2,857
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Gaulton, A., Hersey, A., Nowotka, M., Bento, A. P., Chambers, J., Mendez, D., Mutowo, P., Atkinson, F., Bellis, L. J., Cibrián-Uhalte, E., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1074 · Cited by 2,330
KEGG for representation and analysis of molecular networks involving diseases and drugs
Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M., & Hirakawa, M. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp896 · Cited by 2,322
SchNet – A deep learning architecture for molecules and materials
Schütt, K. T., Sauceda, H. E., Kindermans, P.-J., Tkatchenko, A., & Müller, K.-R. (2018) · The Journal of Chemical Physics · doi:10.1063/1.5019779 · Cited by 2,217
BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities
Liu, T., Lin, Y., Wen, X., Jorissen, R. N., & Gilson, M. K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl999 · Cited by 2,124
Research works printed but not linked: 1
- Feng Q.; Dueva E.; Cherkasov A.; Ester M. PADME: A Deep Learning-Based Framework for Drug-Target Interaction Prediction. arXiv [cs.LG], 2018.
Cited by
Artificial intelligence revolution in drug discovery: A paradigm shift in pharmaceutical innovation
Jarallah, S. J., Almughem, F. A., Alhumaid, N. K., Fayez, N. A., Alradwan, I. A., Alsulami, K. A., Tawfik, E. A., & Alshehri, A. A. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125789 · Cited by 93
Artificial intelligence (AI) in drug design and discovery: A comprehensive review
Bhat, A. R., & Ahmed, S. (2025) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2025.100049 · Cited by 76
Sohn, A., Park, J., Kim, W., Yoon, Y., Lee, S., Ji, J., & Kim, H. (2024) · Toxics · doi:10.3390/toxics12110822 · Cited by 68
“These developments collectively lead to a more efficient and ethical strategy in drug development, reducing the probability of late-stage failures caused by unanticipated toxicity [2,5,49,82,87].”
Overcoming Barriers in Cancer Biology Research: Current Limitations and Solutions
(2025) · doi:10.3390/cancers17132102 · Cited by 44
“However, they may not always accurately predict drug responses in humans because of species-specific differences in pharmacology and safety, and their generation and maintenance can be time-consuming and expensive [13–15].”
AI in fungal drug development: opportunities, challenges, and future outlook
Li, Y., Qiao, Y., Ma, Y., Xue, P., & Ding, C. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1610743 · Cited by 42
Dermawan, D., & Alotaiq, N. (2025) · Scientific Reports · doi:10.1038/s41598-025-93683-1 · Cited by 19
“Such variations underscore the complexity of peptide interactions with host cells and highlight the importance of thorough toxicity assessments in the early stages of drug development 50 .”
Lucero‐Prisno, D. E., Okesanya, O. J., Agboola, A. O., Adebayo, U. O., Adigun, O. A., Ahmed, M. M., Olaleke, N. O., Oso, T. A., Tan, M. I. R. S., Ogaya, J. B., et al. (2025) · Next Bioengineering · doi:10.1016/j.nxbio.2025.100003 · Cited by 22
Artificial Intelligence in Drug Discovery: Integrative Advances From Data to Therapeutic Innovation
Mehran, M. J., Mohammadzadeh, S., Bolideei, M., Barzigar, R., Haider, K. H., Jadgal, N., & Bahrami, Y. (2026) · Drug Development Research · doi:10.1002/ddr.70229 · Cited by 17
“Preclinical research is a critical drug development phase; however, it is time‐consuming and costly, and frequently yields low success rates due to toxicity, poor bioavailability, or lack of efficacy (Hingorani et al. 2019; Amorim et al. 2024).”
Organ‐on‐a‐Chip Technology and Global Multi‐Omics: Current Applications and Future Directions
Cao, X., Xia, C., Li, C., Deng, S., Cao, J., Yang, H., Wang, S., & Chen, P. (2026) · MedComm · doi:10.1002/mco2.70603 · Cited by 14
“The evaluation of drug toxicity and efficacy is crucial for drug development [ 115 ], and accurate dosage is related to treatment effectiveness.”
Fate-tox: fragment attention transformer for E(3)-equivariant multi-organ toxicity prediction
Ha, S., Bang, D., & Kim, S. (2025) · Journal of Cheminformatics · doi:10.1186/s13321-025-01012-5 · Cited by 15
“Functional group-based fragmentation (e.g., RDKit) targets specific reactive centers and toxicophores,including nitro groups, quinones, and Michael acceptors,associated with endpoints such as carcinogenicity and hepatotoxicity [1, 53–55].”
Sadula, A., Chagaleti, B. K., Enneiymy, M., Peddaboina, U. R., Ankireddy, A., Ajmi, M. F. A., & Oubella, A. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.143185 · Cited by 13
Santhiya, P., Bharathi, M. N., Menon, R. R., Rajalakshmi, K., & Manikandan, J. (2025) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2025.100132 · Cited by 16
Su, K., Tang, M., Wu, J., Ye, N., Jiang, X., Zhao, M., Zhang, R., Cai, X., Zhang, X., Li, N., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117476 · Cited by 12
Husain, Z., Saifiuzzaman, M., Bhuia, M. S., Ferdous, J., Hasan, M. S. A., Bappi, M. H., Akbor, M. S., Ansari, S. A., Ansari, I. A., Islam, M. A., et al. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.105469 · Cited by 11
Breaking the oncogenic alliance: advances in disrupting the MTDH–SND1 complex for cancer therapy
Ahmed, N. A., Allam, A. A., Rudayni, H. A., Alkhayl, F. F. A., Lamsabhi, A. M., & Kamel, E. M. (2025) · RSC Advances · doi:10.1039/d5ra04310g · Cited by 12
A review of deep learning approaches for drug synergy prediction in cancer
Li, L., Zhang, H., Zheng, C., & Su, Y. (2025) · npj Drug Discovery. · doi:10.1038/s44386-025-00034-1 · Cited by 14
“Predicting drug-drug toxicity or side effects as an auxiliary task helps the drug synergy prediction model to identify safe and reliable synergistic drug combinations 88,89 .”
AI/ML-based computational models for toxicity prediction
Barua, S., Balaji, B., & Balaji, S. (2026) · Environmental Science and Pollution Research · doi:10.1007/s11356-025-37354-8 · Cited by 18
“Recognising this transformation, regulatory bodies are gradually adapting their frameworks to incorporate AI-based tools, emphasising transparency, explainability, and validation to ensure these technologies can reliably be integrated (Rovida et al. 2015; Amorim et al. 2024).”
Bas, T. G. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091183 · Cited by 8
“Recent guidelines emphasize risk characterization for all components of the formulation, implying the need for systematic assessments incorporating in silico and in vitro models along with clinical data to predict toxicity profiles and ensure patient safety [62,65].”
Toward Integrative Predictive Toxicology: Advanced Methods for Drug Toxicity and Safety Prediction
Gianquinto, E., Bersani, M., Armando, L. G., Davani, L., Cena, C., Simone, A. D., & Spyrakis, F. (2026) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.70065 · Cited by 13
Epigenetic modulation to overcome immune suppression in pancreatic cancer
Drndakova, L., Juhasikova, L., Hlavenova, I., Buociková, V., Durdiakova, S., Mego, M., Buc, M., & Smolková, B. (2026) · Clinical Epigenetics · doi:10.1186/s13148-026-02081-5 · Cited by 9
Çankaya, N., Kebiroglu, H., & Soykan, C. (2025) · Drug and Chemical Toxicology · doi:10.1080/01480545.2025.2468924 · Cited by 7
“…used in environmental science, regulatory settings, and academic research due to its comprehensive range of predictive capabilities and ease of use (amorim et al., 2024). in this study, the in silico toxicity of two terpolymers was investigated using this test program…”
Lulić, A.-M., Marcelić, L., Ramić, A., Kastelić, A. R., Zandona, A., Maraković, N., Primožič, I., & Katalinić, M. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111567 · Cited by 8
Liu, S., Yang, Y., Yang, Y. K., Wei, G., Zhou, L., Lin, J., Yuan, Z., Li, Y., Wu, Z., Liu, T., et al. (2026) · Lab on a Chip · doi:10.1039/d5lc01051a · Cited by 8
Lamberti, A., Villalba‐Riquelme, E., Fernández-Carvajal, A. M., & Ferrer-Montiel, A. V. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1762734 · Cited by 6
“Computational models also offer significant value in predicting drug-related toxicities, including hERG cardiotoxicity and drug-induced liver injury (Amorim et al., 2024), and may also be helpful for drug repositioning.”
Mazri, R., Bourougaa, L., Zekri, A., Ouassaf, M., & Alhatlani, B. Y. (2024) · Applied Sciences · doi:10.3390/app142310817 · Cited by 6
A clinical chemical atlas of xenobiotic toxicity for the Sprague–Dawley rat
Kadyrov, J., Sala, S., Grigoroff, L., Minaee, N. S., Masuda, R., Lodge, S., Ebbels, T. M. D., Reily, M. D., Robertson, D. G., Lehman‐McKeeman, L. D., et al. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04008-0 · Cited by 6
Editorial: Methods in predictive toxicology 2023
Jain, S., Manganelli, S., Gryshkova, V., Rodrigues, M. A., & Magarkar, A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1556352 · Cited by 6
Paranthaman, P., Karuppasamy, R., & Veerappapillai, S. (2025) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-025-01725-2 · Cited by 5
“Increasing literature evidence suggests that the primary reason for the high attrition rate of screened molecules in clinical trials is their deviation from the pharmacokinetic parameters [19].”
Silva, F. A. D. C. E., da Silva, B. R., de Barros, L. R., Beraldo-Neto, E., Maleski, A. L. A., & Alberto-Silva, C. (2025) · Pharmaceuticals · doi:10.3390/ph18050678 · Cited by 5
“The toxicological evaluation of novel bioactive compounds is a critical step in determining their potential for biomedical applications [28].”
In Silico Forensic Toxicology: Is It Feasible?
Šoša, I. (2025) · Toxics · doi:10.3390/toxics13090790 · Cited by 5
“The combination of ML and AI extends well beyond forensic applications; for instance, these technologies are crucial in regulatory affairs toxicology [63,82], where they aid in chemical safety evaluations and risk management by providing quicker and more cost-effective toxicity assessments [1,83].”
InfluentialKumar, S., Misra, S. K., Tiwari, A., Katiyar, A., Awasthi, A., Singh, S. K., Katiyar, A., Dhawan, A., & Kumar, A. (2026) · Talanta · doi:10.1016/j.talanta.2026.129802 · Cited by 7
High-performance NiFe2O4 spinel catalysts: Recyclability and efficiency in multicomponent reactions
Mota, H. P., Anghinoni, J. M., Silva, E. C., Macchion, P., Ferreira, S. S., de Souza, J. F., Lenardao, E. J., & Fajardo, A. R. (2024) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2024.123478 · Cited by 5
Liu, X., & Fan, F. (2026) · Frontiers in Toxicology · doi:10.3389/ftox.2026.1731947 · Cited by 4
“Advancing drug safety assessment relies on bridging the translation gap between animal toxicology findings and clinical outcomes, a challenge with far-reaching consequences for R&D efficiency, regulatory success and patient safety (Waring et al., 2015; Amorim et al., 2024).”
Krishnakumar, H., Manikandan, J., Prabhu, D., & Jeyakanthan, J. (2024) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2024.2443844 · Cited by 4
“By ensuring the safety and efficacy of the identified candidates, pharmacokinetic and toxicity analyses streamline the development process, lead to the discovery of more effective and safer medications, thereby improving patient outcomes [27].”
Boufissiou, A., Abdalla, M., Kadi, I., Hachani, S., Eltayb, W. A., Awadalla, M., Algarni, A. S., Benarfa, A., Bouchareb, A., Benaceur, F., et al. (2025) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-025-00543-z · Cited by 5
“Recent studies have highlighted the critical role of ADMET screening in early drug discovery, emphasizing that early toxicity prediction can streamline drug development (Amorim et al. 2024; Catacutan et al. 2024).”
Mafe, A. N., Bappa, L. D., Sharifi‐Rad, J., Setzer, W. N., & Călina, D. C. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70170 · Cited by 4
“These toxicological insights are vital for future clinical applications and regulatory approval [132].”
Jayaraman, M., Gosu, V., Subbulakshmi, M. M., Kumar, R., Shin, D., & Jeyakanthan, J. (2026) · ACS Omega · doi:10.1021/acsomega.5c05790 · Cited by 4
Diab, H. M., Salem, M. E., Elwahy, A. H. M., Ragheb, M. A., Noamaan, M. A., Algethami, F. K., Abdelhamid, I. A., & Mahmoud, H. K. (2026) · RSC Advances · doi:10.1039/d6ra00243a · Cited by 5
Artificial Intelligence Across the Drug Development Lifecycle
Demyashkin, G. A., Алексеевич, П. М., Zyryanov, S., Yavorskiy, A., Shegai, P., & Kaprin, A. (2026) · Medical Sciences · doi:10.3390/medsci14020248 · Cited by 6
“Most late-stage attrition is linked to issues rooted in the intrinsic physicochemical or biological characteristics of early compounds, which later manifest as inadequate efficacy or unanticipated safety liabilities [120].”
Mustafa, G., Musa, S. I., Shinde, P., Eknure, C., Bachhav, Y. G., & Paradkar, A. R. (2026) · Steroids · doi:10.1016/j.steroids.2026.109799 · Cited by 4
Atunnise, A., Sossou, I. T., Peters, P. S., Ajayi, S. D., Elechukwu, D. A., Salau, T. B., Adebayo, O. L., & Salau, B. A. (2024) · In Silico Pharmacology · doi:10.1007/s40203-024-00277-2 · Cited by 4
“…the case with METH because of its poor VD. Toxicity is estimated to be responsible for the withdrawal of over 30% of drug candidates and is a significant impedance in drug development, and it is responsible for approximately 90% of drugs that fail at the clinical trial phase (Amorim et al. 2024).”
Azole Derivatives as Quorum Sensing Inhibitors: An In Silico Strategy against Bacterial Biofilms
Mishra, S., Kumar, M., Chowdhury, S., Rawat, S., Gupta, D., & Kaur, P. (2025) · ChemistrySelect · doi:10.1002/slct.202405691 · Cited by 5
Ruenchit, P. (2025) · Current Research in Parasitology and Vector-Borne Diseases · doi:10.1016/j.crpvbd.2025.100256 · Cited by 4
Targeting protein kinases in Parkinson’s disease: the emerging role of phytoconstituents
Joshi, D., Kulkarni, M., Parekh, P., Shah, S., Greig, N. H., & Acharya, S. P. (2025) · Nutritional Neuroscience · doi:10.1080/1028415x.2025.2531356 · Cited by 5
“Additionally, these computational techniques are invaluable for predicting the toxicity of compounds, categorizing drugs, and determining bioactivity pro fi les, to thereby contribute signi fi cantly to the safety and e ffi cacy assessments of potential therapeutics [216].”
Predicting the Toxicity of Chemical Compounds via Hyperdimensional Computing
Cumbo, F., Dhillon, K., Joshi, J., Raubenolt, B. A., Chicco, D., Aygün, S., & Blankenberg, D. J. (2026) · Molecular Informatics · doi:10.1002/minf.70052 · Cited by 3
Afroz, M., Hasan, R., Khatun, M. M., Tito, M. H., Shadin, M., Chakma, R., Asiri, M., Altemani, F. H., Altemani, A. H., Bhuia, M. S., et al. (2025) · ChemistryOpen · doi:10.1002/open.202500397 · Cited by 4
Novel liquid-based approaches for transmucosal drug delivery
van Staden, D., Lemmer, H. J. R., Liebenberg, W., & Hamman, J. H. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.12.042 · Cited by 3
Amin, S. A., Kar, S., & Piotto, S. (2026) · Scientific Reports · doi:10.1038/s41598-026-35496-4 · Cited by 3
“Furthermore, making these predictive tools easily accessible and interpretable for medicinal chemists and toxicologists remains a crucial goal 16 .”
Nursyafi, F. S., Pramudito, M. A., Fuadah, Y. N., & Lim, K. M. (2026) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2026.2643659 · Cited by 3
“…learning algorithm, with models typically developed independently for individual toxicity endpoints using narrow structural representations (amorim et al. 2024; ciura et al. 2024; lee h et al. 2025). such fragmented designs often result in unstable performance and lim‑ ited…”
Mondal, H., Bishal, A., Debnath, B., Patel, A., Das, J., & Taj, T. (2026) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-026-00798-2 · Cited by 5
Harnessing AlphaFold: Applications in disease understanding, drug discovery, and vaccine design
Kinde, M. Z., Gessese, A. T., Fenta, M. D., Chanie, S. D., & Sisay, T. (2026) · Results in Engineering · doi:10.1016/j.rineng.2026.111095 · Cited by 3
Choi, G., Bae, S., & Lim, K.-M. (2026) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2026.106031 · Cited by 3
The Future of Drug Development: Leveraging AI for Faster and Safer Innovation
Tomar, P., Goel, F., Pal, A., & Garg, V. K. (2025) · Journal of Advanced Scientific Research · doi:10.55218/jasr.2025160402 · Cited by 2
Engineering Aging: Approaches to Model and Deconstruct Biological Complexity
Joukhdar, H., Lee, S. S., Cox, T. R., Choi, Y. S., Wise, S. G., Young, J. L., Yeo, G. C., & Lim, K. S. (2025) · Advanced Materials · doi:10.1002/adma.202512523 · Cited by 2
Ali, H. B., & Khan, M. B. (2025) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2025.00025 · Cited by 4
Acute and sub-acute toxicological evaluation of a bioactive compound mixture in healthy Wistar rats
Sampath, T. I., Jayasinghe, S., Attanayake, A. P., & Karunaratne, V. (2025) · Drug and Chemical Toxicology · doi:10.1080/01480545.2025.2565712 · Cited by 2
“…therapeutic drug lead can range from the death of an organism to more nuanced changes in cellular structures, behavior, and physiological responses (amorim et al., 2024). herbal remedies are often perceived as safer alternatives to synthetic drugs, yet evidence suggests that prolonged use can…”
Judijanto, L. (2025) · European Journal of Applied Science Engineering and Technology · doi:10.59324/ejaset.2025.3(6).09 · Cited by 4
Subbulakshmi, M. M., Nagarajan, H., Pandi, S., Subramaniyan, S., Berchmans, T., & Jeyakanthan, J. (2025) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2025.2595472 · Cited by 2
de Lima, J. A. L., Franco, L. S., & Lima, L. M. (2026) · ACS Omega · doi:10.1021/acsomega.5c08828 · Cited by 2
Vu, T. L., Nguyen, T. N. L., Tu, Q. T., Nguyen, D. H., & Hoang Mau, C. H. U. (2026) · Vietnam Journal of Biotechnology · doi:10.15625/vjbt-23376 · Cited by 2
The Venom Revolution in Biomedicine: Unlocking Nature’s Toxin Toolkit for Therapeutic Innovation
Bose, D., Srinivasan, K., Patil, S. S., Nayak, A. G., & Hariharapura, R. C. (2026) · Toxicology Reports · doi:10.1016/j.toxrep.2026.102227 · Cited by 3
“Cutting-edge technologies such as proteomics, transcriptomics, and high-throughput functional assays have revolutionised venom research, enabling more precise drug discovery [198].”
Himanshu, Choudhir, G., Sharma, S., Tyagi, T., Islam, A., & Kumar, S. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100281 · Cited by 2
Kumar, A., Jhilta, P., Brahma, M., Kumar, M., Kumar, D., Singh, J., Kumar, D., Maruthi, M., Ansari, A., Singh, S., et al. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.146153 · Cited by 2
Msobo, A., Maphari, P. W., Koorsen, G., Singab, A. N. B., & Mhlongo, M. I. (2026) · In Silico Pharmacology · doi:10.1007/s40203-026-00620-9 · Cited by 2
“These methods facilitate the organisation of complex spectral data, enable rapid annotation of metabolite families, and guide priori-tisation of compounds for downstream molecular docking, molecular dynamics simulations and biological assays (Amorim et al. 2024; Esimbekova et al. 2023).”
The emerging use of artificial intelligence in safety pharmacology and toxicology
Miller, L., Treleaven, I., Amrani, A.-I. E., Rossman, E. I., Winters, B. R., & Pugsley, M. K. (2026) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2026.108424 · Cited by 2
Ma, C., Koh, D., Nishimura, T., Takata, Y., Kameda, Y., Negoro, R., Ishiguro, N., Shibuta, M., Namatame, I., Tetsuka, K., et al. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115887 · Cited by 3
Saeed, M., Arham, M., Zafar, I., Jamal, A., Hussian, M., Usman, M., Bahwerth, F. S., Noman, M., & Hossain, M. B. (2026) · Biotechnology Journal · doi:10.1002/biot.70255 · Cited by 2
Elnagar, M. M., Abou‐El‐Sherbini, K. S., Samir, S., Sharmoukh, W., Abdel-aziz, M. S., & Shaker, Y. M. (2024) · ChemMedChem · doi:10.1002/cmdc.202400680 · Cited by 2
Yamazaki, H., & Shimizu, M. (2025) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5c00157 · Cited by 6
Triterpenes in breast cancer: a systematic review of preclinical evidence in rodents
Prodea, A., Munteanu, A., Jorgovan, M., Bătrîna, O., Mioc, M., Şoica, I., Trandafirescu, C. M., & Şoica, C. M. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1623772 · Cited by 3
GPCR-A17 MAAP: mapping modulators, agonists, and antagonists to predict the next bioactive target
Caniceiro, A. B., Amorim, A. M. B., Rosário‐Ferreira, N., & Moreira, I. S. (2025) · Journal of Cheminformatics · doi:10.1186/s13321-025-01050-z · Cited by 2
“A single receptor can interact with multiple ligands in distinct ways, leading to variable pharmacological effects, and a ligand that functions as an agonist for one receptor may act as an antagonist for another [14].”
Self-citationAsra, F., Kannan, V., Jeyabalan, S., Chintala, S., & Dumala, N. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108691 · Cited by 1
Jamal, T., Singh, R., Bajpai, M., Arif, A., & Parthasarathi, R. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00518 · Cited by 2
AI-designed drugs: clinical development and future directions
Ahmed, R., Akhtar, S., Das, A., Begum, K., Sarma, A., Chakraborty, A., Neog, T., & Banu, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34059-8.00010-5 · Cited by 1
Drug Repurposing In Modern Drug Discovery: Role of In Silico Study
Islam, K. M. T. (2025) · Pharmacon Jurnal Farmasi Indonesia · doi:10.23917/pharmacon.v22i2.13698 · Cited by 1
“Approximately 90% of drugs fail to make it through the process due to improper AMDET profiling (Amorim et al., 2024).”
Babu, A. S., & Rao, K. V. B. (2026) · Preparative Biochemistry & Biotechnology · doi:10.1080/10826068.2026.2635141 · Cited by 1
Lytan, I., Singha, B., Boruah, N., Gogoi, P. P., Longkumer, P., Pucho, M., Dkhar, B., & Sinha, U. B. (2026) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575418750251204104229 · Cited by 3
Hemadyne: accordion-inspired perfusion for microphysiological systems
Kumar, A., Pattanshetti, S., Patel, R. D., Pandey, R., Mahalingam, E., Rahbar, E., & Jain, A. (2026) · Nature Communications · doi:10.1038/s41467-026-73722-9 · Cited by 1
Coelho, F., Ebersol, C. P., Gomes, J. P. M., Strelow, D. N., Hall, T. K., Nascimento, V., Brüning, C. A., Bortolatto, C. F., Lião, L. M., & S, N. J. S. (2026) · Phosphorus, sulfur, and silicon and the related elements · doi:10.1080/10426507.2026.2672728 · Cited by 1
Novel Inhibitors Targeting Urease Promote Fungicidal and Antivirulence Effects in Cryptococcus
Barreto, T. L., Costa, N. E. M., Freire, N. M. L., de Almeida, L. C., Miguel, R. D. A., Costa-Lotufo, L. V., Silva-Rodrigues, G., da Silva, C. M., de Aquino, T. M., Alberto, E. E., et al. (2026) · ACS Omega · doi:10.1021/acsomega.6c03740 · Cited by 1
Narayanan, M. (2026) · Oriental Pharmacy and Experimental Medicine · doi:10.1007/s13596-026-00919-0 · Cited by 1
Khatun, M. M., Bhuia, M. S., Rahaman, M. M., Kamli, H. M., Ansari, S. A., & Islam, M. T. (2025) · Revista Brasileira de Farmacognosia · doi:10.1007/s43450-025-00639-7 · Cited by 2
“It also lowers the chances of expensive failures later in drug development (Issa et al. 2017; Amorim et al. 2024).”
Ngernnak, C., Wongsuwan, S., Ruchirawat, S., & Thasana, N. (2025) · Chemistry - An Asian Journal · doi:10.1002/asia.202500705 · Cited by 1
Rarinca, V., Gurzu, I. L., Nicoară, M., Ciobica, A. S., Todirașcu-Ciornea, E., Gurzu, B., Solcan, C., & Ureche, D. (2025) · Life · doi:10.3390/life15111715 · Cited by 1
“Traditional in vivo toxicity testing using rodents, although informative, faces ethical limitations, high costs and time constraints [11].”
In-silico TOXICITY PREDICTION OF PHENOLIC COMPOUNDS OF Artemisia annua AS ANTICANCER DRUG CANDIDATE
Sari, B. L., Julaeha, E., Rahayu, D. P., & Fitriana, S. A. N. (2024) · RASAYAN Journal of Chemistry · doi:10.31788/rjc.2024.1748869
Sarıaltın, S. Y., & Yalçın, C. Ö. (2025) · Journal of Research in Pharmacy · doi:10.12991/jrespharm.1734646
Xie, L., & Chen, T. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003116
“Secondly, although molecular docking confirmed the binding affinity of PFOA to its targets, its direct impact on carcinogenic pathways still needs to be verified through experiments [ 5 ] .”
Abubakar, A., Balarabe, N. A., Obeid, M. A., Alaofin, W. A., Lawal, A. F., Wahab, K., & Adesokan, A. M. (2025) · Therapeutic Delivery · doi:10.1080/20415990.2025.2545748
Andrew, F. P., Goge, M., Sithebe, S., Ajibade, P. A., & Papo, T. R. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.143688
Baskaran, N., Thangavel, T., & Soundararajan, S. S. (2025) · Journal of Medico Informatics · doi:10.64659/jomi/209942
Adikila, G. G., Hariyanto, Y. A., Tallei, T. E., Suoth, E. J., Sudewi, S., & Fatimawali, F. (2025) · Borneo Journal of Pharmacy · doi:10.33084/bjop.v8i3.7586
Ouchaoui, A. A., Hadad, S. E. E., Bouricha, E. M., Boutayeb, S., Belyamani, L., & Bourais, I. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108709
The medicinal chemist’s map to deep learning: Concepts, applications, and case studies
Mahale, M., Tieghi, R. S., Gogishvili, D., Huynh, D. L., Gomes, R. A., Krishna, S., Dalmas, D. A., Bender, A., & Seal, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00066-2
Alam, M. A., & Amanullah, M. (2026) · Journal of Medico Informatics · doi:10.64659/jomi/211132
From Genetic Engineering to Preclinical Safety: A Study on Recombinant Human Interferons
Ramos, T. I., Villacis-Aguirre, C. A., Lamazares, E., Suárez, V. M., Sandoval, F., Culqui-Tapia, C. N., Martin-Solano, S., Mansilla, R., Ignacio Cabezas, A., Sánchez, O., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262411982
“This demonstrates the importance of evaluating all possible routes from the earliest stages to avoid errors and maximize a biopharmaceutical’s potential [98].”
Gholap, A. D., Khuspe, P. R., & Mane, D. V. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-40511-2.00015-2
Hassan, N. M., Soliman, N. M. M., Abdelfattah, M. M. M., Abdelaal, M. S., Mahmoud, A. M., & ibrahim, F. (2025) · Egyptian Society of Clinical Toxicology Journal · doi:10.21608/esctj.2025.440951.1106
Jannat, N., Haque, M. A., Sharna, J. F., Fatema, K., Rahman, M., Sarker, M. S., Uddin, M. N., Uddin, A. K. M. R., & Patwary, M. A. M. (2025) · South African Journal of Botany · doi:10.1016/j.sajb.2025.09.015
Metaclassifiers and multitask learning for predicting toxicity endpoints with complex mechanism
Kan, H.-L., Chiu, Y.-W., & Tung, C.-W. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30010-3.00006-4
Integrating AI Models for Predicting Drug Efficacy and Toxicity
Tariq, M. U. (2026) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-3373-5258-9.ch007
Metadata
- Authors
- Amorim, A. M. B., Piochi, L. F., Gaspar, A. T., Preto, A. J., Rosário-Ferreira, N., & Moreira, I. S.
- Affiliations
- Centro de Neurociências e Biologia Celular (PT)
- CNC-UC─Center for Neuroscience and Cell Biology, University of Coimbra, Calçada Martim de Freitas, 3000-456 Coimbra, Portugal
- Corresponding author
- Moreira, Irina S.
- Venue
- Chemical Research in Toxicology
- Publisher
- American Chemical Society (ACS)
- Published
- 2024-05-17
- Volume
- 37
- Issue
- 6
- Pages
- 827-849
- ISSN
- 0893-228X (ISSN-L)
- 1520-5010
- PMC
- PMC11187637
- OpenAlex
- W4397001794
- Cited by
- 132
- References
- 140
- Citations by year
- 2026: 69 · 2025: 56 · 2024: 7
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Chemical Research in Toxicology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- European Regional Development Fund
- Funda??o para a Ci?ncia e a Tecnologia (DSAIPA/DS/0118/2020, LA/P/0058/2020, SFRH/BD/144966/2019, UIDB/04539/2020, UIDP/04539/2020)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- drug toxicity prediction, drug safety, drug development attrition, protein-ligand interactions, drug binding affinity, off-target effects, computational toxicology, 3Rs, preclinical toxicity testing
- MeSH terms
- Drug Development, Animals, Humans, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.